Loading
NASDAQHealthcareBiotechnology
Latest quote
$6.505
+$0.045 · +0.70%
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Previous close
$6.505
+$0.045 · +0.70%
After-hours
$6.505
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Day range
Current $6.505
52-week range
Current $6.505
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
30
Expensive
Sentiment
69
Bullish
Risk
52
Elevated Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Day range
Current $6.505
52-week range
Current $6.505
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 1.3M USD | — | — |
| Gross profit | — | — | −1.3M USD | — | — |
| Research and development | 90.3M USD | 73.3M USD | 63.94M USD | 42.24M USD | 25.16M USD |
| Selling, general, and administrative | 22.49M USD | 22.81M USD | 19.76M USD | 18.06M USD | 10.09M USD |
| Operating expenses | 112.79M USD | 96.12M USD | 83.7M USD | 60.3M USD | 35.25M USD |
| Interest income | 6.63M USD | 9.43M USD | 8.59M USD | 1.86M USD | 13K USD |
| Depreciation and amortization | 1.13M USD | 1.22M USD | 1.3M USD | 1.18M USD | 831K USD |
| Operating income | −112.79M USD | −96.12M USD | −84.99M USD | −60.3M USD | −35.25M USD |
| Net income | −106.19M USD | −86.92M USD | −76.41M USD | −58.76M USD | −35.25M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$17.50
169.02% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI21.25M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM9.37M0.01%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF8.13M0.01%95.4B USD0.05%$233.13-0.15%
State Street SPDR S&P Biotech ETFXBI6.23M0.06%10.11B USD0.35%$149.29-0.63%
iShares Russell 2000 Growth ETFIWO3.26M0.02%14.04B USD0.24%$353.47-0.53%
iShares Biotechnology ETFIBB3.25M0.03%10.41B USD0.44%$200.48-1.41%
Dimensional - US Small Cap ETFDFAS2.16M0.01%33.66B USD0.31%$78.10+0.23%
Fidelity Enhanced Small Cap ETFFESM2.13M0.03%6.41B USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
